Home/Pipeline/NPM-133

NPM-133

Type 2 Diabetes

PreclinicalActive

Key Facts

Indication

Type 2 Diabetes

Phase

Preclinical

Status

Active

Company

Vivani Medical

About Vivani Medical

Vivani Medical is a clinical-stage biotechnology company with a mission to free patients from medication adherence challenges through its proprietary, miniaturized, long-term drug implant platform, NanoPortal™. The company has successfully demonstrated the feasibility of its technology in a first-in-human Phase 1 trial (LIBERATE-1) and is now advancing a pipeline focused on GLP-1 agonists for obesity and type 2 diabetes. Its strategy leverages the validated efficacy of GLP-1 drugs while aiming to differentiate through superior convenience (semi-annual or annual dosing) and potentially improved tolerability via steady-state delivery.

View full company profile

Therapeutic Areas

Obesity / Chronic Weight Management Type 2 Diabetes Cardiometabolic Disorders (Veterinary)

Other Type 2 Diabetes Drugs

Drug	Company	Phase	Status
Diabetes Management Gel	Gelteq Limited	Formulation Development	Active
Tolimidone	Biodexa Pharmaceuticals	Phase 2	Acquired Asset
Generic Semaglutide Injection (Obeda)	Dr. Reddy's Laboratories	Approved	Launched in India
BioChaperone® Lispro	Adocia	Phase 3	Active
BioChaperone® Combo (Insulin Glargine / Lixisenatide)	Adocia	Phase 2	Active
Metformin API	USV Biologics Division	Commercial	Active
Empagliflozin	Azico Biophore	Commercial	Active
Sitagliptin Intermediate	AR Life Science	Commercial	Active
AJN003 (LuCI™)	AltrixBio	Pre-clinical	Advancing to Phase 1 (planned 2026)
Sitagliptin Phosphate Polymorph	Morepen Laboratories	Pre‑clinical	Active
Hepatic Denervation for Type 2 Diabetes	Metavention	Feasibility	Active
MVD-1 (SANA)	Eolo Pharma	Discovery	Active